Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 36Lymphoid 28Other hematologic neoplasm 21Thoracic 4Myeloid 3Tumor-Agnostic 2CNS 2Breast 2Other 1Genitourinary 1Gastrointestinal 1

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

fludarabine 64Cyclophosphamide 64venetoclax 58Azacitidine 54fludarabine phosphate 50Specimen Handling 44Whole-Body Irradiation 41ruxolitinib 40Mycophenolic Acid 38Tacrolimus 36Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Decitabine 28Stem Cell Transplantation 27Granulocyte Colony-Stimulating Factor 21Injections 20asciminib 19decitabine and cedazuridine drug combination 18Thiotepa 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Filgrastim 17nilotinib 16X-Rays 14Methotrexate 14Imatinib Mesylate 14Cyclosporine 14Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
dexamethasone acetate × Myeloid × 1 year × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡